Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.

Abstract: Methods for treatment of chronic liver disease and reversing liver fibrosis are provided. These treatments may be achieved using a medical food composition. The medical food is configured specifically for those having chronic liver disease to provide for specific nutritional requirements caused by the chronic liver disease. Testing of the treated patient allows for tracking of progress and to determine if the liver fibrosis is reversed.

Abstract: Provided are a pickering emulsion including: 0.01-20 wt % of particles having an average particle diameter of 10 nm-100 ?m, and 0.01-20 wt % of a non-ionic water-soluble polymer, wherein the particles are positioned on an oil droplet surface, and a method of preparing the same.

Abstract: A medical implant structure is provided comprising a substrate 10 with at least a first surface and a second surface that surfaces differ from one another with regard to at least one property in relation to biological material.

Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Various combinations of formulas were used. Formulas 12, 10 and 5 shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.

Abstract: The present invention relates to the use of a compound according to formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein n is an integer from 0 to 2; the dotted line represents a carbon-carbon single or double bond; and each of R1 to R4, when taken independently from each other, represents a hydrogen atom or represents a R5 or OR5 group, R5 representing a C1 to C5, or even a C1 to C3, alkyl group; and optionally one of the groups R1 to R4 represents —OH; and/or when R1 and R2 are taken together, and/or R3 and R4 are taken together, represent a OCH2O group, provided said groups taken together are adjacent substituents of the phenyl group; as an ingredient in combination with other ingredients to confer, enhance, improve or modify the kokumi or umami taste of a flavored article.

Abstract: Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.

Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.

Abstract: Provided are a nanostructure network and a method of fabricating the same. The nanostructure network includes nanostructures having a poly-crystalline structure formed by self-assembly of the nanostructures. The method includes preparing a nanostructure solution in which nanostructures are dispersed in a first solvent, forming a nanostructure ink by adding the nanostructure solution into a second solvent having a viscosity higher than that of the first solvent, coating a surface of a substrate with the nanostructure ink, and forming a nanostructure network by evaporating the first solvent and the second solvent included in the nanostructure ink coated on the substrate.

Abstract: Cosmetic stick containing: a) one or more UV filters, b) a Fischer-Tropsch wax with a solidification point of 80-85° C. (measured according to ASTM D 938) and a penetration at 25° C. of 0.4-0.9 mm (measured according to ASTM D 1321), the preparation being free from 3-(4-methylbenzylidene)-camphor, 2-hydroxy-4-methoxybenzophenone (INCI: Oxybenzone), 2-ethylhexyl 4-methoxycinnamate (INCI: Octyl Methoxycinnamate) and ethylhexyl-2-cyano-3,3-diphenylacrylate (INCI: Octocrylene).

Abstract: Provided is a topical pharmaceutical gel composition of an amlodipine salt and methods for its use in the treatment of anorectal disease.

Abstract: A dried vitrigel membrane is produced by a method including the following steps of (1) a step of keeping a hydrogel in the inside of a wall surface mold with a shape the same as the desired shape disposed on a substrate, and discharging a part of free water within the hydrogel from a gap between the substrate and the wall surface mold; (2) a step of removing the wall surface mold from the top of the substrate; (3) a step of drying the hydrogel to remove the residual free water, thereby fabricating a vitrified dried hydrogel; (4) a step of rehydrating the dried hydrogel to fabricate a vitrigel membrane; and (5) a step of redrying the vitrigel membrane to remove free water, thereby fabricating a vitrified dried vitrigel membrane.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: A solid anhydrous composition for caring for and/or making up keratin materials comprising: a) at least one triglyceride oil according to formula (I): CH2(OOCR1)CH(OOCR2)CH2(OOCR3) (I) wherein R1, R2 and R3 are independently chosen from C6-C30 alkyl and C6-C30alkenyl; b) at least one triglyceride oil according to formula (II): CH2(OOCR1)CH(OOCR2)CH2(OOCR3) (II) wherein R1, R2 and R3 are independently chosen from C6-C30 alkyl and C6-C30alkenyl, at least one of R1, R2 and R3 is substituted with a hydroxyl; c) at least one pasty compound chosen from an ester of dimer dilinoleic acid and polyol(s) or an ester thereof, and d) at least one wax, wherein the triglyceride oil according to formula (I) and the triglyceride oil according to formula (II) are present in the solid anhydrous composition in a weight ratio less than or equal to 1:1.

Abstract: The present invention relates to a stabilized external preparation comprising thymosin beta 4 (T?4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of T?4. The preparation according to the present invention provides T?4 in a stable state by maintaining the biological activity of T?4 and minimizing the generation of T?4 sulfoxide through oxidization reactions and multimers through aggregation.

Abstract: Topical compositions comprising a corticosteroid, at least one alcohol, and a penetration enhancing agent.

Abstract: The invention provides a plasmid comprising two or more anti-obesity genes. Also provided by the invention are compositions and host cells comprising the plasmid and methods of increasing the metabolic activity in a mammal. The invention provides a plasmid comprising two or more of (a) a nucleic acid sequence encoding islet amyloid polypeptide (IAPP), (b) a nucleic acid sequence encoding leptin (LEP), and (c) a nucleic acid sequence encoding fibronectin type III domain containing 5 (FNDC5).

Abstract: An emulsion cosmetic maintains a concealing ability, allows light in a long wavelength region to transmit efficiently (i.e., an excellent red light selective transmit function), is spread easily, wherein a powder likeness cannot be felt upon use, and provides a natural finish when applied onto the skin. A titanium dioxide powder therefore is composed of particles having an apparent average particle diameter of 100 nm or more and less than 500 nm, an average crystallite diameter of 15 to 30 nm as measured by a X-ray diffraction method and a specific surface area of 10 to 30 m2/g, and each has a shape with radially projected needle-like projections are coagulated, and has a ratio of a longer axis to a shorter axis (i.e., a (longer axis)/(shorter axis) ratio) in the shape of 1.0 to 2.5. The emulsion cosmetic contains 0.1 to 25% by mass of the titanium dioxide powder, 0.1 to 5% by mass of disteardimonium hectorite and 0.1 to 8% by mass of a silicone surfactant.

Abstract: The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acne form rashes, and the like.

Abstract: A biological composition intermixed with a polyampholyte protectant for direct implantation has a mixture of biologic material and a volume of polyampholyte protectant. The mixture of biologic material has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components, or whole cells or combinations of the non-whole cellular components and whole cells, wherein the mixture is compatible with biologic function. The volume of polyampholyte protectant is intermixed with the mixture of biologic material, wherein the polyampholyte protectant is a liquid of a polyamine polymer compound of carboxylated poly-lysine and wherein the polyampholyte protectant forms a three-dimensional bonding shroud externally enveloping each of the non-whole cellular components, if any, and each of the whole cells, if any, of the mixture of biologic material.

Abstract: Xerogels and compositions comprising xerogels comprising a transition metal oxide and silicon oxide xerogel matrix. The xerogels and compositions can be made from mixtures of transition metal alkoxide(s) and tetraalkoxysilane(s) and, optionally, alkyltrialkoxysilane(s), aminoalkyl-, alkylaminoalkyl-, dialkylaminoalkyltrialkoxysilane(s), or a combination thereof. The xerogels and compositions can be used as antifouling coatings on, for example; boats.

Abstract: Disclosed herein are methods of improving skin appearance associated with skin aging. The method comprises the step of applying an anti-aging bioactive composition to a skin surface having at least one sign of aging. The anti-aging bioactive composition is applied for a period of time sufficient to improve the appearance of the at least one sign of aging. In one embodiment, the anti-aging bioactive composition comprises an effective amount of a Nelumbo nucifera (Sacred Lotus) serum fraction. In another embodiment, the anti-aging bioactive composition comprises an effective amount of a Chamomilla recutita (German Chamomile) Flower serum fraction. In other embodiments, the anti-aging bioactive composition can further include a dermatologically acceptable carrier.

Abstract: Staple cartridge assemblies for use with surgical stapling instruments and methods for manufacturing the same are provided. Scaffolds for use with a surgical staple cartridge and methods for manufacturing the same are also provided.

Abstract: In a prior art reactor set up dense aggregates of microorganisms are formed, typically in or embedded in an extracellular matrix. Such may relate to granules, to sphere like entities having a higher viscosity than water, globules, a biofilm, etc. The dense aggregates comprise extracellular polymeric substances, or biopolymers, in particular linear polysaccharides. The present invention is in the field of extraction of a biopolymer from a granular sludge, a biopolymer obtained by such method, and a use of such method.

Abstract: The disclosure provides personal care compositions that comprise a moisturizing agent of formula (I) wherein n is an integer from 2 to 5, R1 is independently H or C1-C3 alkyl and R2 is an unsubstituted linear or branched C1-C6 alkyl, at least one additional moisturizing agent and a cosmetically acceptable vehicle. In particular, the compound of formula (I) is diglycolamine acetamide. The compositions generally improve moisturization of skin and hair.

Abstract: Instantly dissolving buccal fims comprising certain pH modifiers, film formers, film modifiers, and solubilizing agents are provided. Methods of providing the buccal film to enhance the dissolution and bioavailability of low solubility basic drugs, such as dapoxetine hydrochloride, in a subject are also provided.

Abstract: Methods of additively manufacturing components include providing a first control command and/or a second control command to a cart selected from among a plurality of carts. The first control command may be configured to cause the selected cart to autonomously drive or fly to a construction container selected from among a plurality of construction containers and to receive automatically the selected construction container, and, upon the selected cart receiving automatically the selected construction container, to autonomously drive or fly the selected cart to a construction apparatus selected from among a plurality of construction apparatuses.

Abstract: The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-? protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor a (“PPAR?”) to a human or veterinary subject in need of such treatment.

Abstract: Compounds, pharmaceutically acceptable salts, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL2, as well as methods of treatment for diseases involving the biological activity of CCL2.

Abstract: The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, preferably said endoscopic procedure comprising the administration of said pharmaceutical composition to a human with the aim of improving and facilitating the resection of the lesion by raising the area where the lesion is located. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human.

Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.

Abstract: Compositions comprising perforated, unseparated amnion/chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.

Abstract: Provided is a novel preventive or therapeutic agent for celiac disease. A preventive or therapeutic agent for celiac disease, comprising at least one bacterium belonging to the genus Bifidobacterium selected from the group consisting of Bifidobacterium breve and Bifidobacterium bifidum and/or a processed bacterial cell thereof as an active ingredient.

Abstract: Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.

Abstract: Disclosed is a dry composition comprising one or more polyols, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste reconstitutes spontaneously upon addition of the liquid; hence no mechanical mixing is required for said paste to form. The composition may further comprise an extrusion enhancer, such as albumin. Also disclosed are methods of preparing said dry composition, a paste obtained from said dry composition and uses of said dry composition or paste for medical and surgical purposes.

Abstract: The present invention relates to a (poly)hybrid implant made of one or more composite materials, having a polymer matrix and a ceramic-inorganic and/or inorganic component, wherein the polymer matrix has at least one component, selected from the group PDLLA; PLGA, PCL, HDPE, PE, UHMWPE, PEAK, PEEK, PP, PUR, and the ceramic-inorganic component has at least one calcium-phosphate-based component, preferably selected from the group HAP, ?-TCP, ?-TCP and CaCO3. In addition, metallic components can also be introduced, preferably, but not exclusively containing elements such as Mg, Fe, Zn or Sr.

Abstract: A hydrogen-supplying breathable layer in the present disclosure comprises: a thin layer wrapping a hydrogen-producing formula inside, having an airtight outer side as well as an air-permeable inner side on which a plurality of micro pores are opened and featuring a monolayer or a composite layer; a hydrogen-producing formula wrapped inside the thin layer and not dissipated but absorbing moistures in air or liquid water for generation of hydrogen; hydrogen permeating a plurality of micro pores and released to skin and intra-corporal parts. The hydrogen-producing formula in the hydrogen-supplying breathable layer comprises metal peroxides (metal hydroxides or metal hydrides) and aluminum powders (or silica powders); the breathable layer is applicable to a dressing pack or other sanitary paraphernalia in daily lives for relieving non-bacteria inflammations and promoting health care effects.

Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.

Abstract: Achieving enhanced scent expression in antiperspirant compositions and methods.

Abstract: The invention concerns a cartridge for an inhalation device for delivering anaesthetic to a human or animal wherein anaesthetic in said cartridge is dispersed in an anaesthetic control release medium; an inhalation device for use with said cartridge and a formulation comprising at least one selected anaesthetic and anaesthetic control release medium.

Abstract: The present invention discloses elastic macro porous scaffold and a process for the preparation thereof. The present invention also provides a process for the preparation of macroporous, elastic nano particulate scaffolds comprising of coated or grafted cross linkable nanoparticles, and a crosslinker prepared by crosslinking during ice templating, wherein the modulus increases linearly with temperature.

Abstract: Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided.

Abstract: A process to prepare an ethylene-based polymer, said process comprising polymerizing a mixture comprising ethylene, at a pressure greater than, or equal to, 100 MPa, in the presence of at least one free-radical initiator; and in a reactor system comprising at least one reactor and at least one Hyper-compressor, and wherein at least one oil formulation, optionally comprising one or more lubrication agents, is added to the Hyper-compressor; and wherein at least one of the following steps takes place: A) thermally treating the one or more lubrication agents, in an oxygen-free atmosphere, to achieve a peroxide level ?10 ppm, based on the weight of the lubrication agent(s), and then adding said agent(s) to the oil formulation, prior to adding the oil formulation to the Hyper-compressor; or B) thermally treating the oil formulation, in an oxygen-free atmosphere, to achieve a peroxide level ?10 ppm, based on the weight of the oil formulation, prior to adding the oil formulation to the Hyper-compressor; C) a combinat

Abstract: The present application relates to GHB formulations and methods for manufacturing the same.

Abstract: A novel fibrinogen-based tissue adhesive patch is disclosed. The patch comprises a backing made from a non-permeable biocompatible polymer film into which a fibrinogen-based sealant is incorporated. In preferred embodiments of the invention, the biocompatible polymer film comprises units of a biocompatible block copolymer such as a polyethylene glycol-polycaprolactone-DL-lactide copolymer connected by urethane linkages, and the fibrinogen-based sealant comprises fibrinogen, thrombin, and CaCl2. In contrast to similar patches known in the art, the polymer backing serves to seal the tissue to which the patch is applied, and the sealant acts only to bind the patch to the affected tissue. The patch does not include any mesh, woven, or non-woven component. Methods of production and use of the patch are also disclosed.